Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Oncolytics Announces Additional Positive REOLYSIN® Clinical Trial Data from Phase 2 Study

Published: Monday, February 11, 2013
Last Updated: Sunday, February 10, 2013
Bookmark and Share
Study enroll patients with metastatic or recurrent squamous cell carcinoma of the lung.

Oncolytics Biotech Inc. has announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel (REO 021).

The analysis examined percent best overall tumour changes between pre-treatment and up to six treatment cycles.

Of 20 evaluable patients, 19 (95%) exhibited overall tumour shrinkage, (mean (20 patients): 33.7% shrinkage).

A waterfall graph showing individual patient data will be available on the Company's website at

"It's exciting to have 95% of patients in this study exhibit tumour shrinkage and these results further suggest that REOLYSIN may have potential use in neoadjuvant (pre-surgical) settings," said Dr. Brad Thompson , President and CEO of Oncolytics.

Dr. Thompson continued, "Based on these findings we intend to continue to look at REOLYSIN as a treatment for cancers of the lung and cancers that metastasize to the lung."

The study enrolled patients with metastatic or recurrent squamous cell carcinoma of the lung.

The primary endpoint of the study is objective tumour response rates, and the secondary objectives include progression free survival and overall survival.

To date, the Company has observed nine partial responses (PR), nine stable disease (SD) and three progressive disease (PD) by RECIST criteria for a disease control rate (complete response (CR) + PR + SD)) of 86%. The study continues to enroll patients.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncolytics Collaborators Present Preclinical Research on Liver Cancer
Dr. Adel Jebar has presented a poster at the 8th Annual International Conference on Oncolytic Virus in UK.
Tuesday, April 15, 2014
Oncolytics Collaborators Present at UK Oncolytic Virus Conference
Collaborators present translational brain cancer clinical data and immunomodulatory preclinical research.
Tuesday, April 15, 2014
Oncolytics Collaborators to Present Preclinical Research in Multiple Myeloma and Melanoma
Research collaborators will make two poster presentations at the AACR 2014 Annual Meeting.
Tuesday, April 08, 2014
Oncolytics Biotech® Announces Third Quarter 2013 Results
Company announces its financial results and operational highlights.
Monday, November 11, 2013
Oncolytics Biotech® Announces Addition to Senior Management Team
Appointment of Dr. Jeremy Grushcow to the role of General Counsel.
Monday, September 16, 2013
Oncolytics Announces Positive Final Tumour Response Data for U.S. Phase 2 Study of REOLYSIN®
Final progression-free survival and safety data for the study will be reported later in 2013.
Tuesday, September 10, 2013
Oncolytics Meets Primary Endpoint in U.S. Phase 2 Study of REOLYSIN®
Company has met primary overall statistical endpoint in U.S. Phase 2 clinical trial in SCCLC patients.
Tuesday, May 28, 2013
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial
Company announces preliminary results from trial in patients using intravenous administration of REOLYSIN®.
Monday, May 27, 2013
Oncolytics Announces 2012 Year End Results
Company has completed two financings over the last 14 months raising gross proceeds in excess of $50 million.
Tuesday, March 19, 2013
Oncolytics Completes Patient Enrollment in U.S. Phase II Clinical Trial
Investigating REOLYSIN® in combination with gemcitabine in patients with advanced or metastatic pancreatic cancer.
Thursday, February 21, 2013
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 SCLC Clinical Trial
Primary objective of the trial is to assess the antitumor effect of the treatment regimen.
Friday, February 01, 2013
Oncolytics Completes Patient Enrollment in U.S. Phase I Clinical Trial
Phase I clinical trial investigate REOLYSIN® in combination with FOLFIRI in patients with colorectal cancer.
Monday, August 27, 2012
Oncolytics Announces Second Quarter 2012 Results
Company announces completion of enrollment in the first, 80-patient stage of Phase III clinical trial in head and neck cancers.
Monday, August 06, 2012
Oncolytics Enters into Sponsorship Agreement with NCIC CTG
Agreement for randomized phase II study in advanced and metastatic breast cancers.
Friday, June 22, 2012
Oncolytics Announces Publication of Translational Clinical Trial Results in Science Translational Medicine
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.
Thursday, June 14, 2012
Scientific News
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
Dementia Linked to Deficient DNA Repair
Mutant forms of breast cancer factor 1 (BRCA1) are associated with breast and ovarian cancers but according to new findings, in the brain the normal BRCA1 gene product may also be linked to Alzheimer’s disease.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
New Discovery Sheds Light on Disease Risk
Gaps between genes interact to influence the risk of acquiring disease.
Mathematical Model Helps Show How Zebrafish Get Their Stripes
The iconic yellow and blue stripes of zebrafish form dynamically as young fish develop and grow. A mathematical model developed by Brown University researchers helps to show how pigment cells interact to form the pattern.
Epigenome Influenced by Habitat and Lifestyle
Study on Pygmy hunter-gatherer populations and Bantu farmers in Central Africa shows that habitat and lifestyle can impact the epigenome.
Shining Light on Microbial Growth and Death Inside our Guts
Precise measurement of microbial populations in gastrointestinal tracts could be key to identifying novel therapies.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos